ArticleCureus2025
Evaluation of the Humoral Immune Response Following Two Doses of a Coronavirus Disease 2019 Vector-Based Vaccine During the Initial Rollout in Bangladesh.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe rollout of coronavirus disease 2019 (COVID-19) vaccination was crucial in addressing the pandemic in Bangladesh, with the ChAdOx1 vaccine being the primary vaccine administered to most of the population. This study aims to assess the humoral immune response by measuring severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) IgG titers after two doses of the ChAdOx1 vaccine in the Bangladeshi population, irrespective of prior COVID-19 infection status, and to identify antibody titer levels that can predict future COVID-19 infection.
methodsThis was a cross-sectional study conducted among 256 individuals exhibiting COVID-19-like respiratory symptoms who had completed two doses of ChAdOx1 between December 2021 and March 2022. Participants were tested for COVID-19 via nasopharyngeal swabs using real-time polymerase chain reaction (PCR), and SARS-CoV-2 IgG antibody titers (≥33.8 binding antibody unit (BAU)/mL was considered positive) were measured from blood samples with chemiluminescence immunoassay (CLIA) at the COVID-19 laboratory, Department of Virology, Bangladesh Medical University (BMU). Demographic and clinical data were collected, and results were analyzed using IBM SPSS Statistics software version 22 (IBM Corp., Armonk, NY), with a P-value of <0.05 deemed statistically significant.
resultsThe overall seropositivity rate for SARS-CoV-2 IgG antibodies was 86.7%, with a median antibody titer of 501.0 BAU/mL (range: 4.81-2080.0 BAU/mL). Individuals with a prior COVID-19 infection exhibited significantly higher antibody titers (P<0.01) (mean: 1262.12±864.46 BAU/mL, median: 1465 BAU/mL) compared to those without a prior infection. The receiver operating characteristics (ROC) curve analysis (area under the curve (AUC): 0.823, 95% confidence interval (CI): 0.769-0.877, P<0.001) identified a minimum antibody threshold of 359.5 BAU/mL for preliminary immunity against future COVID-19 infections (sensitivity: 81.3%, specificity: 65.9%, Youden's Index: 0.47). Despite vaccination and a history of previous COVID-19, 1.5% of the studied population presented as reinfection with SARS-CoV-2, confirmed by real-time PCR testing. Comorbidity variables, such as diabetes mellitus, asthma, chronic obstructive pulmonary disease (COPD), and hypertension, showed no statistically significant association with the antibody response.
conclusionThis study demonstrated that ChAdOx1 elicits robust antibody responses in the majority of individuals, with significantly stronger reactions observed among those with prior COVID-19 infection. Moreover, it provides effective protection against recurrent infection in this population, provided that a SARS-CoV-2 IgG titer is sustained above the minimum threshold of 359.5 BAU/mL. Nevertheless, additional research is warranted to characterize the SARS-CoV-2 IgG response across diverse populations receiving heterologous or multi-regimen vaccination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.